BRISTOL MYERS SQUIBB CO BMY Income Statement

Bristol myers squibb co (BMY)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09	Sep'08	Jun'08
Revenues
31,006	26,145	24,173	23,857	23,288	22,561	22,037	21,600	21,040	20,776	20,570	20,238	19,965	19,427	18,471	17,618	16,910	16,560	16,531	16,383	16,109	15,879	16,062	16,206	16,365	16,385	16,135	15,806	16,201	17,621	18,884	20,493	21,484	21,244	20,901	20,354	19,688	19,484	19,406	19,396	19,293	18,808	19,029	19,444	0	0	0
Cost of Goods and Services Sold
9,916	8,078	7,236	7,074	6,707	6,467	6,458	6,389	6,333	6,014	5,819	5,545	5,182	4,969	4,515	4,307	4,114	3,909	3,923	3,833	3,811	3,932	4,239	4,407	4,524	4,619	4,421	4,233	4,370	4,610	4,902	5,322	5,558	5,598	5,645	5,518	5,314	5,277	5,296	5,333	5,281	5,140	5,341	5,694	0	0	0
Selling, General and Administrative Expense
5,471	4,871	4,473	4,522	4,577	4,551	4,531	4,590	4,646	4,751	4,964	4,945	4,996	4,979	4,951	4,983	4,880	4,841	5,225	5,078	4,894	4,822	4,860	4,811	4,902	4,939	4,159	4,250	4,212	4,220	4,293	4,241	4,277	4,203	3,987	3,860	3,714	3,686	3,856	3,917	3,945	3,946	3,984	4,196	0	0	0
Advertising and product promotion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	813	786	792	797	870	908	937	957	943	969	979	977	1,040	1,065	1,100	1,136	1,164	1,328	0	0	0
Research and Development Expense
7,172	6,148	5,425	5,323	6,430	6,332	6,890	7,171	6,415	6,468	6,015	5,592	5,179	5,012	5,456	5,450	6,040	5,920	5,193	5,044	4,604	4,534	4,302	4,212	3,747	3,731	3,856	3,914	3,925	3,904	3,830	3,852	3,813	3,839	3,841	3,692	3,591	3,566	3,664	3,660	3,649	3,647	3,373	3,379	0	0	0
Amortization of Acquired Intangible Assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment charge for BMS-986094 intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Provision for restructuring
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	97	133	128	136	115	94	0	0	0
Litigation expense, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	132	162	164	0	0	0
Equity in net income of affiliates
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	367	436	501	550	599	610	0	0	0
Other Nonoperating (Income) Expense
-2,362	-938	-309	610	715	854	1,100	824	1,406	1,685	1,747	1,739	1,607	1,448	870	969	408	187	-284	-330	-119	-210	569	287	-16	-205	-351	-335	-85	80	385	400	380	334	372	356	344	93	180	205	196	381	-52	-74	0	0	0
Costs and Expenses
28,314	21,170	17,564	16,430	17,120	16,593	16,876	17,423	16,085	15,645	15,051	14,343	13,750	13,512	14,052	13,771	14,626	14,483	14,104	13,935	13,265	13,498	12,752	13,086	13,163	13,494	13,600	15,348	15,214	15,281	15,463	13,983	14,243	14,263	14,101	13,770	13,302	13,413	13,428	13,467	13,434	13,206	13,592	14,351	0	0	0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
2,692	4,975	6,609	7,427	6,168	5,968	5,161	4,177	4,955	5,131	5,519	5,895	6,215	5,915	4,419	3,847	2,284	2,077	2,427	2,448	2,844	2,381	3,310	3,120	3,202	2,891	2,535	458	987	2,340	3,421	6,510	7,241	6,981	6,800	6,584	6,386	6,071	5,978	5,929	5,859	5,602	5,437	5,093	0	0	0
Income Tax Expense (Benefit)
1,713	1,515	931	1,203	1,001	1,021	3,701	3,773	4,011	4,156	1,317	1,334	1,388	1,408	998	911	646	446	581	600	552	352	573	423	309	311	-234	-906	-655	-161	613	1,634	1,866	1,721	1,929	1,766	1,607	1,558	1,175	1,229	1,258	1,182	1,302	1,194	0	0	0
Net Earnings from Continuing Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,420	4,135	3,899	0	0	0
Earnings, net of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	285	0	0	0	-	0
Gain on disposal, net of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,157	0	0	0	-	0
Net Earnings from Discontinued Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,442	2,211	2,162	0	0	0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
979	3,460	5,678	6,224	5,167	4,947	1,460	404	944	975	4,202	4,561	4,827	4,507	3,421	2,936	1,638	1,631	1,846	1,848	2,292	2,029	2,737	2,697	2,893	2,580	2,769	1,364	1,642	2,501	2,808	4,876	5,375	5,260	4,871	4,818	4,779	4,513	12,024	12,012	12,042	11,862	6,346	6,061	0	0	0
Net Income (Loss) Attributable to Noncontrolling Interest
25	21	23	21	23	27	28	28	25	-32	-27	-25	-9	50	55	66	64	66	71	58	39	25	20	9	2	17	7	5	174	541	921	1,309	1,551	1,551	1,531	1,498	1,434	1,411	1,380	1,351	1,325	1,250	1,181	1,098	0	0	0
Net Income (Loss) Attributable to Parent
954	3,439	5,655	6,203	5,144	4,920	1,432	376	919	1,007	4,229	4,586	4,836	4,457	3,366	2,870	1,574	1,565	1,775	1,790	2,253	2,004	2,717	2,688	2,891	2,563	2,762	1,359	1,468	1,960	1,887	3,567	3,824	3,709	3,340	3,320	3,345	3,102	10,644	10,661	10,717	10,612	5,165	4,963	0	0	0
Earnings Per Share [Abstract]
Net earnings from continuing operations attributable to Bristol-Myers Squibb Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,239	0	0	0	-	-
Net earnings from discontinued operations attributable to Bristol-Myers Squibb Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,373	0	0	0	-	-
Net Earnings Attributable to Bristol-Myers Squibb Company
954	3,439	5,655	6,203	5,144	4,920	1,432	376	919	1,007	4,537	4,858	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,165	4,963	0	0	0
Basic Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.41	0.45	0.44	0.33	0.30	0.36
Diluted Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.41	0.45	0.44	0.33	0.29	0.36
Earnings Per Share, Basic
-0.34	-0.74	0.83	0.88	1.05	0.71	1.16	0.23	0.91	-1.42	0.52	0.56	0.95	0.53	0.72	0.70	0.72	-0.11	0.42	-0.08	0.71	0.01	0.43	0.20	0.57	0.44	0.42	0.33	0.37	0.57	-0.43	0.38	0.65	0.50	0.57	0.53	0.58	0.28	0.55	0.54	0.43	4.05	0.49	0.49	0.32	1.30	0.38
Earnings Per Share, Diluted
-0.34	-0.73	0.83	0.87	1.04	0.71	1.16	0.23	0.91	-1.40	0.51	0.56	0.94	0.53	0.72	0.69	0.71	-0.12	0.42	-0.08	0.71	0.01	0.43	0.20	0.56	0.43	0.42	0.32	0.37	0.57	-0.43	0.38	0.64	0.51	0.56	0.52	0.57	0.28	0.55	0.53	0.43	4.05	0.48	0.49	0.32	1.28	0.38
Cash dividends declared per common share
-	-	-	-	-	-	-	-	-	-	0.39	0.39	0.39	-	0.38	0.38	0.38	0.38	0.37	0.37	0.37	0.37	0.36	0.36	0.36	0.36	0.35	0.35	0.35	0.35	0.34	0.34	0.34	0.34	0.33	0.33	0.33	0.33	0.32	0.32	0.32	0.32	0.31	0.31	0.31	0.31	0.31
Net product sales [Member]
Revenues
30,002	25,174	23,227	22,892	22,322	21,581	20,912	20,341	19,650	19,258	19,026	18,656	18,318	17,702	16,750	15,810	14,950	14,045	13,423	12,714	11,912	11,660	11,718	11,900	12,154	12,304	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Alliance and other revenues [Member]
Revenues
1,004	971	946	965	966	980	1,125	1,259	1,390	1,518	1,544	1,582	1,647	1,725	1,721	1,808	1,960	2,515	3,108	3,669	4,197	4,219	4,344	4,306	4,211	4,081	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-